Progress in islet transplantation in patients with type 1 diabetes mellitus

Treatments in Endocrinology

Volumn 5, Issue 3, 2006, Pages 147-158

  Truong, Wayne ^a   Shapiro, A M James ^a,b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; ALEMTUZUMAB; ATORVASTATIN; BELATACEPT; CORTICOSTEROID; DACLIZUMAB; DEXTRAN; ESTRADIOL; ETANERCEPT; FINGOLIMOD; GLYCOSYLATED HEMOGLOBIN; GROWTH FACTOR; IMMUNOMODULATING AGENT; IODIXANOL; NICOTINAMIDE; RAPAMYCIN; RITUXUMAB; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; INSULIN;

CELL FUNCTION; DONOR SELECTION; GRAFT REJECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; LIVING DONOR; MOUTH ULCER; NONHUMAN; OVARY CYST; PANCREAS ISLET TRANSPLANTATION; PERIPHERAL EDEMA; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; UNSPECIFIED SIDE EFFECT; ALLOTRANSPLANTATION; DIABETES MELLITUS, TYPE 1;

DIABETES MELLITUS, TYPE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; LIVING DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 33646503541     PISSN: 11756349     EISSN: 11756349     Source Type: Journal    
DOI: 10.2165/00024677-200605030-00003     Document Type: Review

References (117)

1. Minkowski O. Untersuchungen uber den diabetes mellitus nac exgtirpation der pankreas. Berl Klin Wschr 1892; 29: 90-3
2. Williams P. Notes on diabetes treated with extract and by grafts of sheep's pancreas. BMJ 1894; 2: 1303-4
3. Banting F. Extract from Banting's notebook 2am October 31st: Academy of Medicine notebook. Toronto (ON): Archives of Toronto University, 1920
4. Kelly WD, Lillehei RC, Merkel FK, et al. Allotransplantation of the pancreas and duodenum along with the kidney in diabetic nephropathy. Surgery 1967; 61 (6): 827-37
5. Lacy PE, Kostianovsky M. Method for the isolation of intact islets of Langerhans from the rat pancreas. Diabetes 1967; 16 (1): 35-9
6. Ballinger WF, Lacy PE. Transplantation of intact pancreatic islets in rats. Surgery 1972; 72 (2): 175-86
7. Sutherland DE, Gruessner RW, Dunn DL, et al. Lessons learned from more than 1000 pancreas transplants at a single institution. Ann Surg 2001; 233 (4): 463-501
8. Tosatti E, Valente U, Campisi C, et al. Segmental pancreas autotransplantation in man following total or near total pancreatectomy for serious recurrent chronic pancreatitis. Transplant Proc 1980; 12 (4 Suppl. 2): 15-8
9. Valente U, Ferro M, Campisi C, et al. Report of clinical cases of islet autotransplantation. Transplant Proc 1980; 12 (4 Suppl. 2): 202-4
10. Valente U, Ferro M, Campisi C, et al. Allogeneic pancreatic islet transplantation by means of artificial membrane chambers in 13 diabetic recipients. Transplant Proc 1980; 12 (4 Suppl. 2): 223-6
11. Najarian JS, Sutherland DE, Matas AJ, et al. Human islet transplantation: a preliminary report. Transplant Proc 1977; 9 (1): 233-6
12. Sutherland DE, Matas AJ, Goetz FC, et al. Transplantation of dispersed pancreatic islet tissue in humans: autografts and allografts. Diabetes 1980; 29 Suppl. 1: 31-44
13. Largiader F, Kolb E, Binswanger U, et al. Successful allotransplantation of an island of Langerhans. Schweiz Med Wochenschr 1979; 109 (45): 1733-6
14. Kolb E, Largiader F. Clinical islet transplantation. Transplant Proc 1980; 12 (4 Suppl. 2): 205-7
15. Gray DW, McShane P, Grant A, et al. A method for isolation of islets of Langerhans from the human pancreas. Diabetes 1984; 33 (11): 1055-61
16. Ricordi C, Lacy PE, Scharp DW. Automated islet isolation from human pancreas. Diabetes 1989; 38 Suppl. 1: 140-2
17. Lake SP, Bassett PD, Larkins A, et al. Large-scale purification of human islets utilizing discontinuous albumin gradient on IBM 2991 cell separator. Diabetes 1989; 38 Suppl. 1: 143-5
18. Robertson GS, Chadwick DR, Contractor H, et al. The optimization of large-scale density gradient isolation of human islets. Acta Diabetol 1993; 30 (2): 93-8
19. Scharp DW, Lacy PE, Santiago JV, et al. Insulin independence after islet transplantation into type I diabetic patient. Diabetes 1990; 39 (4): 515-8
20. Scharp DW, Lacy PE, Santiago JV, et al. Results of our first nine intraportal islet allografts in type 1, insulin-dependent diabetic patients. Transplantation 1991; 51 (1): 76-85
21. Tzakis AG, Ricordi C, Alejandro R, et al. Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet 1990; 336 (8712): 402-5
22. Farney AC, Najarian JS, Nakhleh RE, et al. Autotransplantation of dispersed pancreatic islet tissue combined with total or near-total pancreatectomy for treatment of chronic pancreatitis. Surgery 1991; 110 (2): 427-37; discussion 437-9
23. Socci C, Falqui L, Davalli AM, et al. Fresh human islet transplantation to replace pancreatic endocrine function in type 1 diabetic patients: report of six cases. Acta Diabetol 1991; 28 (2): 151-7
24. Gores PF, Najarian JS, Stephanian E, et al. Insulin independence in type I diabetes after transplantation of unpurified islets from single donor with 15-deoxyspergualin. Lancet 1993; 341 (8836): 19-21
25. Jaeger C, Hering BJ, Dyrberg T, et al. Islet cell antibodies and glutamic acid decarboxylase antibodies in patients with insulin-dependent diabetes mellitus undergoing kidney and islet-after-kidney transplantation. Transplantation 1996; 62 (3): 424-6
26. Brendel MD, Hering BJ, Schultz AO, et al. International Islet Transplant Registry report, newsletter #8. Giessen: University of Giessen, 1999
27. Alejandro R, Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in type 1 diabetes. Diabetes 1997; 46 (12): 1983-9
28. Bretzel RG, Brandhorst D, Brandhorst H, et al. Improved survival of intraportal pancreatic islet cell allografts in patients with type-1 diabetes mellitus by refined peritransplant management. J Mol Med 1999; 77 (1): 140-3
29. Shapiro AM, Lakey JR, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343 (4): 230-8
30. Shapiro AM, Ricordi C, Hering B. Edmonton's islet success has indeed been replicated elsewhere [letter]. Lancet 2003; 362 (9391): 1242
31. Ault A. Edmonton's islet success tough to duplicate elsewhere [letter]. Lancet 2003; 361 (9374): 2054
32. Lakey JR, Cavanagh TJ, Zieger MA, et al. Evaluation of a purified enzyme blend for the recovery and function of canine pancreatic islets. Cell Transplant 1998; 7 (4): 365-72
33. Linetsky E, Bottino R, Lehmann R, et al. Improved human islet isolation using a new enzyme blend, liberase. Diabetes 1997; 46 (7): 1120-3
34. Horaguchi A, Merrell RC. Preparation of viable islet cells from dogs by a new method. Diabetes 1981; 30 (5): 455-8
35. Lakey JR, Warnock GL, Shapiro AM, et al. Intraductal collagenase delivery into the human pancreas using syringe loading or controlled perfusion. Cell Trans plant 1999; 8 (3): 285-92
36. Scharp DW, Kemp CB, Knight MJ, et al. The use of Ficoll in the preparation of viable islets of Langerhans from the rat pancreas. Transplantation 1973; 16 (6): 686-9
37. Olack B, Swanson C, McLear M, et al. Islet purification using Euro-Ficoll gradients. Transplant Proc 1991; 23 (1 Pt 1): 774-6
38. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37 (4): 413-20
39. Latif ZA, Noel J, Alejandro R. A simple method of staining fresh and cultured islets. Transplantation 1988; 45 (4): 827-30
40. Scharp D, Lacy P, Ricordi C, et al. Human islet transplantation in patients with type I diabetes. Transplant Proc 1989; 21 (1 Pt 3): 2744-5
41. Warnock GL, Kneteman NM, Ryan EA, et al. Continued function of pancreatic islets after transplantation in type I diabetes. Lancet 1989; II (8662): 570-2
42. McAlister VC, Gao Z, Peltekian K, et al. Sirolimus-tacrolimus combination immunosuppression. Lancet 2000; 355 (9201): 376-7
43. Shapiro AM, Geng Hao E, Lakey JR, et al. Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts. Transplantation 2002; 74 (11): 1522-8
44. Birkeland SA, Beck-Nielsen H, Rohr N, et al. Steroid-free immunosuppression in kidney-islet transplantation: a long-term follow-up [letter]. Transplantation 2002; 73 (9): 1527; author reply 1528
45. Rabinovitch A, Suarez-Pinzon WL. Cytokines and their roles in pancreatic islet beta-cell destruction and insulin-dependent diabetes mellitus. Biochem Pharmacol 1998; 55 (8): 1139-49
46. Brattstrom C, Wilczek H, Tyden G, et al. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65 (9): 1272-4
47. Morrisett JD, Abdel-Fattah G, Hoogeveen R, et al. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 2002; 43 (8): 1170-80
48. Kneteman NM, Lakey JR, Wagner T, et al. The metabolic impact of rapamycin (sirolimus) in chronic canine islet graft recipients. Transplantation 1996; 61 (8): 1206-10
49. Rother KI, Harlan DM. Challenges facing islet transplantation for the treatment of type 1 diabetes mellitus. J Clin Invest 2004; 114 (7): 877-83
50. Ryan EA, Paty BW, Senior PA, et al. Risks and side effects of islet transplantation. Curr Diab Rep 2004; 4 (4): 304-9
51. Fiorina P, Gremizzi C, Maffi P, et al. Islet transplantation is associated with an improvement of cardiovascular function in type 1 diabetic kidney transplant patients. Diabetes Care 2005; 28 (6): 1358-65
52. Fiorina P, Venturini M, Folli F, et al. Natural history of kidney graft survival, hypertrophy, and vascular function in end-stage renal disease type 1 diabetic kidney-transplanted patients: beneficial impact of pancreas and successful islet cotransplantation. Diabetes Care 2005; 28 (6): 1303-10
53. Schmied BM, Ulrich A, Matsuzaki H, et al. Maintenance of human islets in long-term culture. Differentiation 2000; 66 (4-5): 173-80
54. Hering BJ, Kandaswamy R, Harmon JV, et al. Transplantation of cultured islets from two-layer preserved pancreases in type 1 diabetes with anti-CD3 antibody. Am J Transplant 2004; 4 (3): 390-401
55. Goss JA, Schock AP, Brunicardi FC, et al. Achievement of insulin independence in three consecutive type-1 diabetic patients via pancreatic islet transplantation using islets isolated at a remote islet isolation center. Transplantation 2002; 74 (12): 1761-6
56. Matsumoto S, Qualley SA, Goel S, et al. Effect of the two-layer (University of Wisconsin solution-perfluorochemical plus O2) method of pancreas preservation on human islet isolation, as assessed by the Edmonton Isolation Protocol. Transplantation 2002; 74 (10): 1414-9
57. Ricordi C, Fraker C, Szust J, et al. Improved human islet isolation outcome from marginal donors following addition of oxygenated perfluorocarbon to the cold-storage solution. Transplantation 2003; 75 (9): 1524-7
58. Birkeland SA, Beck-Nielsen H, Rohr N, et al. Islet and kidney transplantation using ATG and cyclosporin monotherapy and a central facility for islet isolation and purification. Transplant Proc 1995; 27 (6): 3150-7
59. Shapiro AM, Lakey JR, Paty BW, et al. Strategic opportunities in clinical islet transplantation. Transplantation 2005; 79 (10): 1304-7
60. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54 (7): 2060-9
61. Ryan EA, Lakey JR, Paty BW, et al. Successful islet transplantation: continued insulin reserve provides long-term glycemic control. Diabetes 2002; 51 (7): 2148-57
62. Johnson JA, Kotovych M, Ryan EA, et al. Reduced fear of hypoglycemia in successful islet transplantation. Diabetes Care 2004; 27 (2): 624-5
63. Fiorina P, Folli F, Maffi P, et al. Islet transplantation improves vascular diabetic complications in patients with diabetes who underwent kidney transplantation: a comparison between kidney-pancreas and kidney-alone transplantation. Transplantation 2003; 75 (8): 1296-301
64. Fiorina P, Folli F, Zerbini G, et al. Islet transplantation is associated with improvement of renal function among uremic patients with type I diabetes mellitus and kidney transplants. J Am Soc Nephrol 2003; 14 (8): 2150-8
65. Shapiro AM. Islet transplants and impact on secondary diabetic complications: does C-peptide protect the kidney? J Am Soc Nephrol 2003; 14 (8): 2214-6
66. Ryan EA, Paty BW, Senior PA, et al. Beta-score: an assessment of beta-cell function after islet transplantation. Diabetes Care 2005; 28 (2): 343-7
67. Couzin J. Diabetes. Islet transplants face test of time. Science 2004; 306 (5693): 34
68. Frank A, Deng S, Huang X, et al. Transplantation for type I diabetes: comparison of vascularized whole-organ pancreas with isolated pancreatic islets. Ann Surg 2004; 240 (4): 631-40; discussion 640-3
69. Ryan EA, Lakey JR, Rajotte RV, et al. Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol. Diabetes 2001; 50 (4): 710-9
70. Davalli AM, Ogawa Y, Scaglia L, et al. Function, mass, and replication of porcine and rat islets transplanted into diabetic nude mice. Diabetes 1995; 44 (1): 104-11
71. Davalli AM, Ogawa Y, Ricordi C, et al. A selective decrease in the beta cell mass of human islets transplanted into diabetic nude mice. Transplantation 1995; 59 (6): 817-20
72. Bennet W, Sundberg B, Groth CG, et al. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes 1999; 48 (10): 1907-14
73. Moberg L, Johansson H, Lukinius A, et al. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet 2002; 360 (9350): 2039-45
74. Titus TT, Horton PJ, Badet L, et al. Adverse outcome of human islet-allogeneic blood interaction. Transplantation 2003; 75 (8): 1317-22
75. Piemonti L, Leone BE, Nano R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51 (1): 55-65
76. Korsgren O, Nilsson B, Berne C, et al. Current status of clinical islet transplantation. Transplantation 2005; 79 (10): 1289-93
77. Robertson RP. Islet transplantation as a treatment for diabetes: a work in progress. N Engl J Med 2004; 350 (7): 694-705
78. Brandhorst H, Brandhorst D, Hering BJ, et al. Body mass index of pancreatic donors: a decisive factor for human islet isolation. Exp Clin Endocrinol Diabetes 1995; 103 Suppl. 2: 23-6
79. Bertuzzi F, Garancini P, Socci TC, et al. Lessons from in vitro perifusion of pancreatic islets isolated from 80 human pancreases. Cell Transplant 1999; 8 (6): 709-12
80. Arita S, Une S, Ohtsuka S, et al. Increased islet viability by addition of beraprost sodium to collagenase solution. Pancreas 2001; 23 (1): 62-7
81. Matsumoto S, Rigley TH, Qualley SA, et al. Efficacy of the oxygen-charged static two-layer method for short-term pancreas preservation and islet isolation from nonhuman primate and human pancreata. Cell Transplant 2002; 11 (8): 769-77
82. Rose NL, Palcic MM, Helms LM, et al. Evaluation of Pefabloc as a serine protease inhibitor during human-islet isolation. Transplantation 2003; 75 (4): 462-6
83. Brandhorst H, Brandhorst D, Hesse F, et al. Successful human islet isolation utilizing recombinant collagenase. Diabetes 2003; 52 (5): 1143-6
84. Hering BJ, Kandaswamy R, Ansite JD, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293 (7): 830-5
85. Shapiro AM, Ricordi C. Unraveling the secrets of single donor success in islet transplantation. Am J Transplant 2004; 4 (3): 295-8
86. Contreras JL, Eckstein C, Smyth CA, et al. Brain death significantly reduces isolated pancreatic islet yields and functionality in vitro and in vivo after transplantation in rats. Diabetes 2003; 52 (12): 2935-42
87. Eckhoff DE, Eckstein C, Smyth CA, et al. Enhanced isolated pancreatic islet recovery and functionality in rats by 17beta-estradiol treatment of brain death donors. Surgery 2004; 136 (2): 336-45
88. Goto M, Johansson H, Maeda A, et al. Low molecular weight dextran sulfate prevents the instant blood-mediated inflammatory reaction induced by adult porcine islets. Transplantation 2004; 77 (5): 741-7
89. Moberg L, Olsson A, Berne C, et al. Nicotinamide inhibits tissue factor expression in isolated human pancreatic islets: implications for clinical islet transplantation. Transplantation 2003; 76 (9): 1285-8
90. Titus T, Badet L, Gray DW. Islet cell transplantation for insulin-dependent diabetes mellitus: perspectives from the present and prospects for the future. Expert Rev Mol Med 2000; 2000: 1-28
91. Deschamps JY, Roux FA, Gouin E, et al. Reluctance of French patients with type 1 diabetes to undergo pig pancreatic islet xenotransplantation. Xenotransplantation 2005; 12 (3): 175-80
92. Rios AR, Conesa CC, Ramirez P, et al. Public attitude toward xenotransplantation: opinion survey. Transplant Proc 2004; 36 (10): 2901-5
93. Teran-Escandon D, Teran-Ortiz L, Ormsby-Jenkins C, et al. Psychosocial aspects of xenotransplantation: survey in adolescent recipients of porcine islet cells. Transplant Proc 2005; 37 (1): 521-4
94. Komoda H, Miyagawa S, Omori T, et al. Survival of adult islet grafts from transgenic pigs with N-acetylglucosaminyltransferase-III (GnT-III) in cynomolgus monkeys. Xenotransplantation 2005; 12 (3): 209-16
95. Hermann M, Pirkebner D, Draxl A, et al. In the search of potential human islet stem cells: is tetranectin showing us the way? Transplant Proc 2005; 37 (2): 1322-5
96. Thomas D, Suthanthiran M. Optimal modes and targets of gene therapy in transplantation. Immunol Rev 2003; 196: 161-75
97. Halban PA. Cellular sources of new pancreatic beta cells and therapeutic implications for regenerative medicine. Nat Cell Biol 2004; 6 (11): 1021-5
98. Chen NK, Sivalingam J, Tan SY, et al. Plasmid-electroporated primary hepatocytes acquire quasi-physiological secretion of human insulin and restore euglycemia in diabetic mice. Gene Ther 2005; 12 (8): 655-67
99. Nakajima-Nagata N, Sakurai T, Mitaka T, et al. In vitro induction of adult hepatic progenitor cells into insulin-producing cells. Biochem Biophys Res Commun 2004; 318 (3): 625-30
100. Zalzman M, Gupta S, Giri RK, et al. Reversal of hyperglycemia in mice by using human expandable insulin-producing cells differentiated from fetal liver progenitor cells. Proc Natl Acad Sci U S A 2003; 100 (12): 7253-8
101. Zalzman M, Anker-Kitai L, Efrat S. Differentiation of human liver-derived, insulin-producing cells toward the beta-cell phenotype. Diabetes 2005; 54 (9): 2568-75
102. Bulotta A, Farilla L, Hui H, et al. The role of GLP-1 in the regulation of islet cell mass. Cell Biochem Biophys 2004; 40 (3 Suppl.): 65-78
103. Lopez-Talavera JC, Garcia-Ocana A, Sipula I, et al. Hepatocyte growth factor gene therapy for pancreatic islets in diabetes: reducing the minimal islet transplant mass required in a glucocorticoid-free rat model of allogeneic portal vein islet transplantation. Endocrinology 2004; 145 (2): 467-74
104. Nielsen JH, Svensson C, Galsgaard ED, et al. Beta cell proliferation and growth factors. J Mol Med 1999; 77 (1): 62-6
105. Ogawa N, List JF, Habener JF, et al. Cure of overt diabetes in NOD mice by transient treatment with anti-lymphocyte serum and exendin-4. Diabetes 2004; 53 (7): 1700-5
106. Rooman I, Bouwens L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 2004; 47 (2): 259-65
107. Matsumoto S, Okitsu T, Iwanaga Y, et al. Insulin independence after living-donor distal pancreatectomy and islet allotransplantation. Lancet 2005; 365 (9471): 1642-4
108. Mittal VK, Toledo-Pereyra LH, Sharma M, et al. Acute portal hypertension and disseminated intravascular coagulation following pancreatic islet autotransplantation after subtotal pancreatectomy. Transplantation 1981; 31 (4): 302-4
109. Shapiro AM, Lakey JR, Rajotte RV, et al. Portal vein thrombosis after transplantation of partially purified pancreatic islets in a combined human liver/islet allograft. Transplantation 1995; 59 (7): 1060-3
110. Villiger P, Ryan EA, Owen R, et al. Prevention of bleeding after islet transplantation: lessons learned from a mulitvariate analysis of 132 cases at a single institution. Am J Transplant 2005; 5 (12): 2992-8
111. Han D, Xu X, Baidal D, et al. Assessment of cytotoxic lymphocyte gene expression in the peripheral blood of human islet allograft recipients: elevation precedes clinical evidence of rejection. Diabetes 2004; 53 (9): 2281-90
112. Bell E, Cao X, Moibi JA, et al. Rapamycin has a deleterious effect on MIN-6 cells and rat and human islets. Diabetes 2003; 52 (11): 2731-9
113. Adams AB, Shirasugi N, Durham MM, et al. Calcineurin inhibitor-free CD28 blockade-based protocol protects allogeneic islets in nonhuman primates. Diabetes 2002; 51 (2): 265-70
114. Fu F, Hu S, Deleo J, et al. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720. Transplantation 2002; 73 (9): 1425-30
115. Wijkstrom M, Kenyon NS, Kirchhof N, et al. Islet allograft survival in nonhuman primates immunosuppressed with basiliximab, RAD, and FTY720. Transplantation 2004; 77 (6): 827-35
116. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002; 346 (22): 1692-8
117. Contreras JL, Jenkins S, Eckhoff DE, et al. Stable alpha- and beta-islet cell function after tolerance induction to pancreatic islet allografts in diabetic primates. Am J Transplant 2003; 3 (2): 128-38